These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 27511181

  • 1. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
    Overwater IE, Rietman AB, Bindels-de Heus K, Looman CW, Rizopoulos D, Sibindi TM, Cherian PJ, Jansen FE, Moll HA, Elgersma Y, de Wit MC.
    Neurology; 2016 Sep 06; 87(10):1011-8. PubMed ID: 27511181
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy and safety of rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis].
    Zou L, Liu Y, Pang L, Ju J, Shi Z, Zhang J, Chen X, Su X, Hu L, Shi X, Yang X.
    Zhonghua Er Ke Za Zhi; 2014 Nov 06; 52(11):812-6. PubMed ID: 25582464
    [Abstract] [Full Text] [Related]

  • 3. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
    Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN.
    Pediatr Neurol; 2020 Apr 06; 105():59-61. PubMed ID: 31924480
    [Abstract] [Full Text] [Related]

  • 4. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.
    Eur J Paediatr Neurol; 2013 Sep 06; 17(5):479-85. PubMed ID: 23567018
    [Abstract] [Full Text] [Related]

  • 5. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P.
    Pediatr Neurol; 2015 Mar 06; 52(3):281-9. PubMed ID: 25591831
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study.
    He W, Chen J, Wang YY, Zhang MN, Qian-Lu, Wang QH, Luo XM, Chen XQ, Zou LP.
    Seizure; 2020 Jul 06; 79():20-26. PubMed ID: 32416565
    [Abstract] [Full Text] [Related]

  • 7. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
    J Pediatr; 2014 May 06; 164(5):1195-200. PubMed ID: 24518170
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
    Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN.
    Ann Neurol; 2013 Nov 06; 74(5):679-87. PubMed ID: 23798472
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN.
    Eur J Paediatr Neurol; 2013 Nov 06; 17(6):631-8. PubMed ID: 23845174
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.
    Krueger DA, Capal JK, Curatolo P, Devinsky O, Ess K, Tzadok M, Koenig MK, Narayanan V, Ramos F, Jozwiak S, de Vries P, Jansen AC, Wong M, Mowat D, Lawson J, Bruns S, Franz DN, TSCure Research Group.
    Eur J Paediatr Neurol; 2018 Nov 06; 22(6):1066-1073. PubMed ID: 30005812
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex.
    Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, Ten Hoopen LW, van der Vaart T, Jansen FE, Elgersma Y, Moll HA, de Wit MY, ENCORE Expertise Centre for Neurodevelopmental Disorders.
    Neurology; 2019 Jul 09; 93(2):e200-e209. PubMed ID: 31217257
    [Abstract] [Full Text] [Related]

  • 15. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
    Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA.
    Epilepsia; 2016 Oct 09; 57(10):1617-1624. PubMed ID: 27696387
    [Abstract] [Full Text] [Related]

  • 16. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN.
    N Engl J Med; 2010 Nov 04; 363(19):1801-11. PubMed ID: 21047224
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.
    Curatolo P, Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, de Vries PJ, Dlugos DJ, Fan J, Ridolfi A, Pelov D, Voi M, French JA.
    Lancet Child Adolesc Health; 2018 Jul 04; 2(7):495-504. PubMed ID: 30169322
    [Abstract] [Full Text] [Related]

  • 18. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N, Han L, Wong M.
    Epilepsia; 2015 Jul 04; 56(7):1088-97. PubMed ID: 26122303
    [Abstract] [Full Text] [Related]

  • 19. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP, Krueger DA.
    Neuro Oncol; 2015 Dec 04; 17(12):1550-9. PubMed ID: 26289591
    [Abstract] [Full Text] [Related]

  • 20. The use of rapamycin in patients with tuberous sclerosis complex: Long-term results.
    Canpolat M, Gumus H, Kumandas S, Coskun A, Per H.
    Epilepsy Behav; 2018 Nov 04; 88():357-364. PubMed ID: 30305233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.